GlassScriptPhysician profile
Richard Dean Campbell
NPI 1932180759
$729.00
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $210 · 2021: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $173.26 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $149.88 | 2019-2021 | |
| Pfizer INC. | $101.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.28 | 2020-2021 | |
| Mdd US Operations, LLC | $57.22 | 2019 | |
| Biodelivery Sciences International, INC. | $55.08 | 2019-2021 | |
| Abbott Laboratories | $42.56 | 2019-2020 | |
| Almatica Pharma LLC | $30.89 | 2021 | |
| Shionogi INC | $17.39 | 2019 | |
| Electronic Waveform Lab, INC. | $15.45 | 2019 | |
| Assertio Therapeutics, INC. | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.